biomedicina slovenica


pr=Bedard : 15

  1. Veitch Zachary; Ribnikar Domen; Tilley Derek; Tang Patricia; King Karen; Bedard Philippe L.; Lupichuk Sasha; Cescon David W.
    No evidence of disease versus residual disease in long-term responders to first-line HER2-targeted therapy for metastatic breast cancer
    2022
  2. Ribnikar Domen; Stukalin Igor; Bedard Philippe L.; Hamilton Robert J.; Jewett Michael; Warde Padraig; Chung Peter; Templeton Arnoud J.; Amir Eitan; Lewin Jeremy
    The prognostic value of neutrophil-to-lymphocyte ratio in metastatic testicular cancer
    2020
  3. Ribnikar Domen; Bedard Philippe L.
    Utility of molecular tools for extended adjuvant endocrine therapy decisions in early breast cancer
    2017
  4. Vera-Badillo Francisco Emilio; Chang Martin; Kuruzar Gordana; Ocaña Alberto; Templeton Arnoud J.; Šeruga Boštjan; Goldstein Robyn; Bedard Philippe L.; Tannock Ian; Amir Eitan
    Association between androgen receptor expression, Ki-67 and the 21-gene recurrence score in non-metastatic, lymph node-negative, estrogen receptor-positive and HER2-negative breast cancer
    2015
  5. Tibau B.; Bedard Philippe L.; Vera-Badillo Francisco Emilio; Templeton Arnoud J.; Ocaña Alberto; Šeruga Boštjan; Barnadas Agustí; Amir Eitan
    Author financial conflicts of interest (FCOIs) in clinical practice guidelines (CPGs) for systemic anti-cancer drugs
    2014
  6. Tibau Ariadna; Bedard Philippe L.; Srikanthan Amirrtha; Ethier Josee-Lyne; Vera-Badillo Francisco Emilio; Templeton Arnoud J.; Ocaña Alberto; Šeruga Boštjan; Barnadas Agustí; Amir Eitan
    Author financial conflicts of interest, industry funding, and clinical practice guidelines for anticancer drugs
    2015
  7. Vera-Badillo Francisco Emilio; Chang Martin; Kuruzar Gordana; Ocaña Alberto; Templeton Arnoud J.; Šeruga Boštjan; Al-Mubarak Mustafa; Goldstein Robyn; Bedard Philippe L.; Tannock Ian; Amir Eitan
    Association between androgen receptor (AR) expression, Ki-67, and the 21-gene recurrence score in early breast cancer
    2014
  8. Amir Eitan; Šeruga Boštjan; Ocaña Alberto; Carlsson Lindsay; Bedard Philippe L.
    Pooled analysis of outcomes of T1a/bN0, HER2-amplified breast cancer
    2011
  9. Pezzo R. C.; Šeruga Boštjan; Krzyzanowska M. K.; Bedard Philippe L.
    Quality of safety reporting in oncology-randomized controlled trials (RCTs)
    2011
  10. Vera-Badillo Francisco; Templeton Arnoud J.; Gouveia Paulo de; Diaz-Padilla Ivan; Bedard Philippe L.; Al-Mubarak Mustafa; Šeruga Boštjan; Tannock Ian; Ocaña Alberto; Amir Eitan
    Androgen receptor expression and outcomes in early breast cancer
    2013
  11. Vera-Badillo Francisco; Templeton Arnoud J.; Gouveia Paulo de; Diaz-Padilla Ivan; Bedard Philippe L.; Al-Mubarak Mustafa; Šeruga Boštjan; Tannock Ian; Ocaña Alberto; Amir Eitan
    Androgen receptor expression and outcomes in early breast cancer
    2014
  12. Templeton Arnoud; Ocaña Alberto; Šeruga Boštjan; Vera-Badillo Francisco; Carlsson Lindsay; Bedard Philippe L.; Amir Eitan
    Management of small HER2 overexpressing tumours
    2012
  13. Amir Eitan; Bedard Philippe L.; Ocaña Alberto; Šeruga Boštjan
    Benefits and harms of detecting clinically occult breast cancer
    2012
  14. Snoj Nataša; Bedard Philippe L.; De Azambuja Evandro; Cardoso Fatima; Piccart Martine
    Are we HER-ting for innovation in neoadjuvant breast cancer trial design?
    2009
  15. Cardoso F; Bedard PL; Winer EP; Pagani O; Senkus-Konefka E; Fallowfield LJ; Kyriakides S; Costa A; Čufer T; Albain KS
    International Guidelines for Management of Metastatic Breast Cancer: Combination vs Sequential Single-Agent Chemotherapy
    2009


New search      Comments      Top of page Institute for Biostatistics and Medical Informatics